Omega-3 for Longevity: What the DO-HEALTH Trial Actually Shows

Omega-3 is one of the very few longevity supplements with a randomized trial that moved an aging biomarker — which immediately makes it more interesting than the dozens of candidates resting on mouse data or pure association. In 2024–25, a secondary analysis of the large DO-HEALTH trial reported that 1 gram a day of omega-3 slowed several epigenetic "aging clocks," with the effect adding to vitamin D and exercise. That's a genuinely notable result. But the size of the effect, the fact that it's measured on a surrogate marker rather than a hard outcome, and DO-HEALTH's mostly-negative primary results all matter enormously for how much weight to put on it. This page separates the real signal from the headline. For the wider map of what's earned its place versus what's hype, start with our pillar on longevity medicine: what's proven vs hyped.

What omega-3 is

Omega-3 fatty acids are long-chain polyunsaturated fats — chiefly EPA and DHA from marine sources (fish, fish oil, algae), plus the shorter-chain ALA from plants like flax. They're incorporated into cell membranes and feed anti-inflammatory signaling pathways, which is the mechanistic basis for nearly every health claim attached to them. Supplements are typically standardized to a combined EPA+DHA dose; the DO-HEALTH trial used 1 g/day. Omega-3 is genuinely an essential nutrient — deficiency is a real thing — so the relevant longevity question is not "does the body need any?" but "does adding it beyond a normal diet slow aging or extend life?" Those are very different questions, and the marketing routinely blurs them.

The DO-HEALTH clock result: the strongest piece

DO-HEALTH was a large, well-run randomized trial in adults aged 70+ across five European countries, testing vitamin D, omega-3 (1 g/day), and a simple home strength-exercise program in a factorial design. In 2025, Nature Aging published a pre-specified analysis of DNA-methylation "aging clocks" in a subset of participants. The finding that drew headlines: omega-3 supplementation slowed the pace of biological aging on several epigenetic clocks, the three interventions had additive effects, and combining all three produced the largest slowing¹. Translated into plain terms, the omega-3 effect was on the order of a few months of "clock" slowing over the three-year trial — small in absolute size, but statistically real and, crucially, from a randomized design rather than an observational one.

That randomized framing is what sets omega-3 apart from most of this site's supplements: the taurine and ergothioneine cases rest on association, while here someone actually assigned people to omega-3 versus placebo and measured a change. That's a higher tier of evidence. But two cautions are load-bearing, and they're why this earns a B rather than an A.

Caveat one: it's a surrogate endpoint

An epigenetic clock is a biomarker of aging, not aging itself. These clocks — Horvath-style methylation clocks and pace-of-aging measures like DunedinPACE² — correlate with age and, to varying degrees, with mortality risk across populations. But no epigenetic clock has been validated as a treatment target: we do not yet know that moving the clock by a few months with a supplement translates into actually living longer or healthier. It's entirely possible to nudge a surrogate without changing the outcome it stands in for — the history of medicine is littered with examples. So the honest statement is: DO-HEALTH showed omega-3 slowed a marker of aging by a small amount. It did not show omega-3 made people live longer. Those are different claims, and only the first is proven.

Caveat two: DO-HEALTH's primary results were largely negative

This is the context the clock headline tends to drop. DO-HEALTH's primary paper, published in JAMA in 2020, tested whether vitamin D, omega-3, and exercise improved six hard endpoints — blood pressure, non-vertebral fractures, physical performance, infection rate, and cognitive function — and found that none of the three interventions produced a significant benefit on those outcomes³. In other words, the same trial that later showed a small epigenetic-clock effect for omega-3 had already shown that omega-3 did not meaningfully reduce fractures, infections, or cognitive decline in these older adults. A supplement that slows a biomarker but didn't move the clinical endpoints in its own headline trial deserves cautious, not breathless, framing.

What the big outcome trials show

Zoom out to the largest randomized omega-3 trials for hard outcomes and the picture stays sober. VITAL, a trial of over 25,000 U.S. adults, found that 1 g/day of marine omega-3 did not significantly reduce the primary endpoints of major cardiovascular events or invasive cancer versus placebo⁴. A meta-analysis pooling ten trials and roughly 78,000 people likewise found omega-3 supplementation produced no significant reduction in cardiovascular disease, coronary death, or major vascular events⁵, and a large Cochrane review concluded that increasing long-chain omega-3 has little or no effect on all-cause mortality or cardiovascular events⁶. There are pockets of benefit — high-dose prescription EPA in specific high-risk, high-triglyceride patients is a real exception — but for the general goal of "take fish oil to live longer," the best randomized evidence does not support a meaningful mortality benefit. The longevity case for omega-3 therefore rests largely on the surrogate clock data, not on hard-outcome trials.

Where omega-3 plausibly fits the biology

None of this means omega-3 is inert. Chronic inflammation and other catalogued hallmarks of aging⁷ are exactly the pathways omega-3 modulates, which is why the small clock effect is mechanistically believable rather than a fluke. Omega-3's value may also be greatest in people with genuinely low intake — correcting a shortfall, rather than piling supplementation onto an already fish-rich diet. The DO-HEALTH result is best read as "this is biologically plausible and produced a small randomized signal worth following," not "this is a proven life-extender."

Safety

Omega-3 is among the better-tolerated supplements: the main side effects are fishy aftertaste, burping, and mild GI upset, and at typical doses (around 1 g/day EPA+DHA, as in DO-HEALTH and VITAL) it was well tolerated in large trials³⁴. The notable caveat is a modest, dose-related signal for atrial fibrillation in some high-dose omega-3 trials, so more is not automatically better. As always, "well tolerated" is a separate claim from "proven to extend life," and people on blood thinners or facing surgery should talk to a clinician.

The grade

The bottom line

Omega-3 earns a Grade B — and it's instructive to see why it grades higher than most of this site's supplements while still falling short of an A. The reason it's a B and not a C is real: DO-HEALTH produced a randomized signal that omega-3 slowed epigenetic aging clocks, additive with vitamin D and exercise — that's a genuinely higher tier of evidence than the associations behind taurine or ergothioneine. The reason it's a B and not an A is equally real: the effect was small (a few months of clock slowing), it sits on a surrogate marker no one has validated as a treatment target, the same trial's hard clinical endpoints were null, and the largest outcome trials show no meaningful mortality benefit. Omega-3 is a sensible, well-tolerated supplement — especially if your intake is low — with the best randomized aging-biomarker data in the category and no proof yet that it extends human life. For where it lands against the rest, see our best longevity supplements, rated by evidence roundup; for how easily a moved biomarker gets sold as a benefit, see longevity biomarker panels; and for the one supplement with even stronger functional-outcome data, compare creatine for aging. For programs that pair supplements with real clinical oversight, see our graded best longevity clinics hub.